Cellular and molecular responses to topoisomerase I poisons: Exploiting synergy for improved radiotherapy

Annals of the New York Academy of Sciences

Volumn 922, Issue , 2000, Pages 274-292

  Miyamoto, Shigeki ^a   Huang, Tony T ^b   Wuerzberger Davis, Shelly ^c   Bornmann, William G ^a   Pink, John J ^b   Tagliarino, Colleen ^a   Kinsella, Timothy J ^c   Boothman, David A ^a,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LAPACHONE; DNA TOPOISOMERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXIDOREDUCTASE; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL ACTIVITY; CELL CYCLE; CELL SURVIVAL; CONFERENCE PAPER; CYTOTOXICITY; DNA DAMAGE; DNA STRAND BREAKAGE; GENOTOXICITY; HUMAN; IONIZING RADIATION; NONHUMAN; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0034517127     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb07045.x     Document Type: Conference Paper

References (60)

1. DNA topoisomerases
2. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
3. Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during β-lapachone-mediated apoptosis
4. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks
5. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
6. A model for tumor cell killing by topoisomerase poisons
7. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer
8. Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor
9. Inhibition of potentially lethal DNA damage repair in human tumor cells by β-lapachone, an activator of topoisomerase I
10. β-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin
11. β-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: A p53-independent response
12. Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells
13. Inhibition of radiation-induced neoplastic transformation by beta-lapachone
14. Induction of apoptosis in MCF-7: WS8 breast cancer cells by β-lapachone
15. Induction of DNA topoisomerase II-mediated DNA cleavage by β-lapachone and related naphthoquinones
16. Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents
17. NAD(P)H:quinone oxidoreductase (NQO1) activity is the principal determinant of β-lapachone cytotoxicity
18. β-Lapachone-induced apoptosis in human prostate cancer cells: Involvement of NQO1/xip3
19. NF-κB - Ten years after
20. Rel/NF-κB/IκB family: Intimate tales of association and dissociation
21. Rel/NF-κB transcription factors and the control of apoptosis
22. IκB interacts with the nuclear localization sequences of the subunits of NF-κB: A mechanism for cytoplasmic retention
23. IκB/MAD-3 masks the nuclear localization signal of NF-κB p65 and requires the transactivation domain to inhibit NF-κB p65 DNA binding
24. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB
25. IKK-1 and IKK-2: Cytokine-activated IκB kinases essential for NF-κB activation
26. IκB kinase-β: NF-κB activation and complex formation with IκB kinase-a and NIK
27. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation
28. Stimulation-dependent IκBα phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway
29. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway
30. UV-induced transcription from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and UV-induced secretion of an extracellular factor that induces HIV-1 transcription in nonirradiated cells
31. NF-κB activation by ultraviolet light not dependent on a nuclear signal
32. Topoisomerase poisons activate the transcription factor NF-κB in ACH-2 and CEM cells
33. Identification and characterization of X-ray-induced proteins in human cells
34. Isolation of x-ray-inducible transcripts from radioresistant human melanoma cells
35. Coordinate modulation of Sp1, NF-κB, and p53 in confluent human malignant melanoma cells after ionizing radiation
36. Novel IκBα degradation process in WEHI231 murine immature B cells
37. Enucleation of mammalian cells by cytochalasin B. I. Characterization of anucleate cells
38. TARF6 is a signal transducer for interleukin-1
39. Autoregulation of IκBα activity
40. NF-κB activation by camptothecin: A linkage between nuclear DNA damage and cytoplasmic signaling events
41. Quantitation of β-lapachone and 3-hydroxy-β-lapachone in human plasma samples by reversed-phase high-performance liquid chromatography
42. β-Lapachone greatly enhances MMS lethality to human fibroblasts
43. Coordinate inhibition of DNA synthesis and thymidylate synthase activity following DNA damage and repair
44. Radiation lethality enhancement with 9-aminocamptothecin: Comparison to other topoisomerase I inhibitors
45. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: Report of a synergistic effect between topotecan and radiation
46. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation
47. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives
48. DNA topoisomerase I-targeting drugs as radiation sensitizers
49. Topoisomerase I inhibitor with potential radiosensitizing effect
50. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SKF 104864)
51. Interaction of ionizing radiation with topotecan in two human tumor cell lines
52. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases
53. Additive and supraadditive interaction between ionizing radiation and pazelliptine, a DNA topoisomerase inhibitor, in Chinese hamster V-79 fibroblasts
54. NAD(P)H:quinone oxidoreductase activity is the principal determinant of β-lapachone cytotoxicity
55. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA
56. Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells
57. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin
58. A nuclear export signal in the N-terminal regulatory domain of IκBα controls cytoplasmic localization of inactive NF-κB/IκBα complexes
59. Suppression of tumor necrosis factor-activated nuclear transcription factor-κB, activator protein-1, c-Jun N-terminal kinase, and apoptosis by β-lapachone
60. Bcl-2 protects against β-lapachone-mediated caspase-3 activation and apoptosis in human myeloid leukemia (HL-60) cells